179 related articles for article (PubMed ID: 36545746)
1. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
El-Hajj Fuleihan G; Clines GA; Hu MI; Marcocci C; Murad MH; Piggott T; Van Poznak C; Wu JY; Drake MT
J Clin Endocrinol Metab; 2023 Feb; 108(3):507-528. PubMed ID: 36545746
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.
Seisa MO; Nayfeh T; Hasan B; Firwana M; Saadi S; Mushannen A; Shah SH; Rajjoub NS; Farah MH; Prokop LJ; Wang Z; Fuleihan GE; Drake MT; Murad MH
J Clin Endocrinol Metab; 2023 Feb; 108(3):585-591. PubMed ID: 36545700
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hypercalcaemia of malignancy in adults.
Mc Donald D; Drake MT; Crowley RK
Clin Med (Lond); 2023 Sep; 23(5):503-507. PubMed ID: 37775175
[TBL] [Abstract][Full Text] [Related]
4. Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study.
Bassatne A; Murad MH; Piggott T; Drake MT; Rahme M; El-Hajj Fuleihan G
J Clin Endocrinol Metab; 2023 Feb; 108(3):563-584. PubMed ID: 36545699
[TBL] [Abstract][Full Text] [Related]
5. Commentary on the endocrine society clinical practice guideline on the "treatment of hypercalcemia of malignancy in adults".
El-Hajj Fuleihan G; Drake MT
Metabolism; 2023 Jun; 143():155553. PubMed ID: 37028591
[No Abstract] [Full Text] [Related]
6. Treatment of Hypercalcemia of Malignancy.
Chakhtoura M; El-Hajj Fuleihan G
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
9. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
10. Hypercalcemia of Malignancy.
Hu MI
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):721-728. PubMed ID: 34774243
[TBL] [Abstract][Full Text] [Related]
11. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
[TBL] [Abstract][Full Text] [Related]
12. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
13. Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors.
Chukir T; Liu Y; Hoffman K; Bilezikian JP; Farooki A
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1115-23. PubMed ID: 31841590
[TBL] [Abstract][Full Text] [Related]
14. No. 367-2019 Canadian Guideline for Physical Activity throughout Pregnancy.
Mottola MF; Davenport MH; Ruchat SM; Davies GA; Poitras V; Gray C; Jaramillo Garcia A; Barrowman N; Adamo KB; Duggan M; Barakat R; Chilibeck P; Fleming K; Forte M; Korolnek J; Nagpal T; Slater L; Stirling D; Zehr L
J Obstet Gynaecol Can; 2018 Nov; 40(11):1528-1537. PubMed ID: 30297272
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
16. Values and other decisional factors regarding treatment of hypercalcaemia of malignancy: a systematic review protocol.
Bassatne A; Rahme M; Piggott T; Murad MH; Hneiny L; El-Hajj Fuleihan G
BMJ Open; 2021 Oct; 11(10):e051141. PubMed ID: 34635523
[TBL] [Abstract][Full Text] [Related]
17. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
[TBL] [Abstract][Full Text] [Related]
19. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.
Qaseem A; Hicks LA; Etxeandia-Ikobaltzeta I; Shamliyan T; Cooney TG; ; Cross JT; Fitterman N; Lin JS; Maroto M; Obley AJ; Tice JA; Tufte JE
Ann Intern Med; 2023 Feb; 176(2):224-238. PubMed ID: 36592456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
